A new carbon membrane could help make proton therapy beams more precisely controlled—not by increasing the dose delivered to a tumor, but by reducing unwanted proton scattering as the beam is formed. In a 2025 study, ultra-clean monolayer amorphous carbon (UC-MAC) produced fewer fragment-proton scattering events than the graphene and commercial carbon films tested. The result is a materials advance, not evidence of better patient outcomes or a clinically ready treatment.
How UC-MAC could make a proton beam more precise
The Nature Nanotechnology study used UC-MAC as a membrane to split molecular hydrogen ions (H₂⁺) into protons. The researchers report that unwanted fragment-proton scattering events were about half as frequent with UC-MAC as with single-crystal graphene, and 40 times fewer than with commercial carbon thin films. These are comparisons from the reported experiment, not rankings of complete proton-therapy systems.
In proton therapy, beam direction and control matter because the treatment relies on directing protons toward a target. A thin membrane that causes less scattering could help preserve beam sharpness. The National University of Singapore (NUS) describes the material’s potential relevance to controlling beam current and direction; the study does not establish that using it improves tumor targeting in patients.
What the material is—and how it differs from graphene
Despite the “graphene-like” description, UC-MAC is not graphene. Graphene has an ordered hexagonal carbon lattice. UC-MAC is a disordered single layer of carbon with angstrom-scale pores and five-, six- and seven-membered carbon rings. Its structure distinguishes it from the regular arrangement in graphene.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
#1 Best Overall
Lin and colleagues report an industry-compatible disorder-to-disorder synthesis method that produced wafer-scale UC-MAC in seconds, without detectable metal contamination. NUS’s 2025 release describes an 8-inch sheet grown in seconds; the journal abstract separately describes wafer-scale production on a timescale of seconds. Those results show manufacturing progress, but do not establish routine commercial supply.
How UC-MAC compares with other carbon membranes
| Comparison | What the sources report | What that establishes |
|---|---|---|
| Unwanted fragment-proton scattering | Lin et al. report about half as many events as with single-crystal graphene, and 40 times fewer than with commercial carbon thin films. | A favorable experimental comparison for UC-MAC in the tested beam-forming setup; not a clinical ranking of treatment systems. |
| Thickness and beam-current modulation | The Nature Nanotechnology abstract identifies minimum thickness and current modulation as desirable considerations. It does not provide a comparative clinical performance result for those factors. | Potential design considerations, not proof that UC-MAC improves treatment outcomes. |
| Manufacturing | The paper reports wafer-scale synthesis in seconds; NUS describes an 8-inch sheet grown in seconds. | A scale-and-speed advance, not evidence of a product, commercial availability or regulatory readiness. |
What “boost proton therapy” does—and does not—mean
Here, “boost” refers to the possibility of sharper beam formation or improved beam control through reduced scattering. The Nature Nanotechnology paper reports proton-beam formation and scattering, not a test showing that UC-MAC increases the dose deposited in a tumor.
Other proton-therapy materials research examines different questions. For example, Cook et al. studied tissue-equivalent phantom materials used to model tissues and support range and dosimetry measurements. Their 2023 study reported that commercial bone-equivalent materials had a relative range difference of up to 8%; optimized formulations mimicked target tissues within 1–2% for mass density and relative stopping power. These are phantom-material results, not performance figures for UC-MAC.
A separate 2016 study hosted by UCL examined gold nanoparticles, not carbon membranes. At a gold nanoparticle concentration of 5.5 mg/ml and proton energy of 226 MeV, it reported a 21% experimental dose-to-film enhancement and a 2.2 mm distal-edge shift. Those results concern dose deposition and Bragg-peak behavior in that experiment; they cannot be attributed to UC-MAC.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Likewise, a 2022 study in Vacuum reported a linear Raman response for graphene oxide foils over an absorbed-dose range from about 100 Gy to about 114 MGy. That is a separate dosimetry application, not evidence that UC-MAC is validated for clinical treatment.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What the findings mean for patients and availability
The reported work is an experimental materials and beam-control result. The paper and NUS release do not report patient outcomes, clinical validation, regulatory status or routine commercial availability. The described industry-compatible synthesis method and wafer-scale production are promising manufacturing steps, but do not show that hospitals can obtain or use UC-MAC membranes in treatment systems.
For now, the appropriate takeaway is potential: lower scattering in the tested setup may offer a route to better beam precision if the membrane can be developed and validated for clinical systems. The sources do not establish whether, when or in what form that could happen.
Quick Recap
Sources
- National University of Singapore, “New carbon material sharpens proton beams, potentially boosting cancer treatment precision” (2025)
- Lin et al., Nature Nanotechnology (2025)
- Cook et al., Physics in Medicine & Biology (2023)
- Gold nanoparticle proton-therapy study (2016), hosted by UCL
- Torrisi et al., Vacuum (2022)
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
